Healthcare -
Biotechnology - NASDAQ - US
$ 18.13
6.27 %
$ 1.44 B
Market Cap
-4.2
P/E
Price Target
Average
87.93%
Revenue Forecast
Estimate
1185.61%
EBIT
Estimate
--37.90%
Net Income
Estimate
31.17%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Viridian Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for VRDN of $34.1 , with forecasts ranging from
a
low of
$20 to a high of $56 .
VRDN Lowest Price Target
Wall Street Target
20 USD
10.31%
VRDN Average Price Target
Wall Street Target
34.1 USD
87.93%
VRDN Highest Price Target
Wall Street Target
56 USD
208.88%
REVENUE FORECAST
Revenue Forecast Chart VRDN
EBIT FORECAST
EBIT Forecast Chart VRDN
NET INCOME FORECAST
Net Income Chart VRDN